1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

General Session

Discussion in 'Otsuka' started by anonymous, Aug 18, 2017 at 1:11 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This is the best we have???
     

  2. anonymous

    anonymous Guest

    This is sad. The "talent",organization, and overall feeling I get is that of a start-up organization or contract sales. We are not world class or on par with the real leaders in our industry. We appear as amateurs.
     
  3. anonymous

    anonymous Guest

    Lundbeck employees look awkward, unsure of what to say, unprepared, and probably wishing they were someplace else.
     
  4. anonymous

    anonymous Guest

    It's painful to watch the home office joking around when we have some serious launch challenges- low speaker funds, few starter kits, and no patient ready LCCs in our markets. Not funny.
     
  5. anonymous

    anonymous Guest

    They laugh because they have no idea what is going on. Pretty obvious.
     
  6. anonymous

    anonymous Guest

    Lundbeck Rex/Trintellix here. Are you guys at the bi-polar launch meeting? I know our Alpha reps are dreading like hell to launch this indication!